As the national debt surpasses $36.2 trillion, looming Medicare cuts could shock millions. Experts warn that these budget reductions may have dire consequences for healthcare access, especially for the elderly and disabled.
After a steep 18% drop, UnitedHealth Group's shares saw a modest rebound as analysts maintain positive ratings despite the company withdrawing its guidance and the CEO's resignation. Will the stock recover?
In a surprising move, UnitedHealth Group CEO Andrew Witty has stepped down, citing personal reasons. Board chairman Stephen Hemsley takes over as the company navigates significant industry challenges.
In a surprising turn of events, UnitedHealth Group announces a new CEO as Andrew Witty steps down. Stephen Hemsley returns to lead amid stock market challenges and ongoing scrutiny over corporate practices.
In a surprising turn of events, Stephen Hemsley is back as CEO of UnitedHealth after the abrupt departure of current leader Witty. The company faces significant challenges, including recent cyberattacks and rising medical costs.
In a bold move, President Trump is set to sign an executive order mandating the U.S. health department to negotiate lower drug prices with pharmaceutical companies. This could drastically change healthcare costs for millions of Americans.
President Trump unveils a groundbreaking executive order aimed at slashing U.S. drug prices by matching them to those in developed countries. Will this initiative reshape the pharmaceutical landscape and benefit American patients?
In a landmark move, President Trump signs an Executive Order aimed at reducing prescription drug prices for Americans, aligning them with those in other wealthy nations. This initiative seeks to curb unfair pricing practices and ensure a fair deal for U.S. patients.
President Trump signs an executive order reviving the 'most favored nation' policy to slash drug costs by linking U.S. prices to lower prices abroad. Will this finally bring relief to American patients?
President Trump is set to sign an executive order aiming to lower drug prices in the US by aligning them with prices in wealthy nations. This 'most favored nation' model could face legal challenges.
